In short
KYV-101, a fully-human anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, is currently being studied in clinical trials for various autoimmune diseases. These trials aim to assess the safety, tolerability, and clinical effectiveness of KYV-101 in treating conditions such as idiopathic inflammatory myopathies, diffuse cutaneous systemic sclerosis, systemic lupus erythematosus with nephritis, and ANCA-associated vasculitis. The studies involve administering a single dose of KYV-101 to participants and monitoring their progress over an extended period.
At a glance
- Drug Name
- KYV-101
- Type of Therapy
- Fully-human anti-CD19 CAR T-cell therapy
- Conditions Studied
- Idiopathic inflammatory myopathies, Diffuse cutaneous systemic sclerosis, Systemic lupus erythematosus with nephritis, ANCA-associated vasculitis
- Administration
- Single intravenous infusion of 1x10^8 CAR+ T cells
- Pre-treatment
- Lymphodepleting chemotherapy with cyclophosphamide and fludarabine
- Primary Outcomes
- Safety (incidence and severity of adverse events), ANCA seroconversion rate, clinical efficacy
- Follow-up Duration
- Up to 2 years
- Key Secondary Outcomes
- Changes in immunoglobulin levels, B-cell and T-cell numbers, disease activity scores, time to relapse, duration of remission
What is KYV-101?
KYV-101 is an innovative medical treatment known as a CAR T-cell therapy. Specifically, it is described as an autologous fully-human anti-CD19 CAR T-cell immunotherapy. Let's break down what this means:
- Autologous: This means the therapy uses the patient's own cells, which are modified and then given back to the patient.
- Fully-human: The components used to modify the cells are derived from human sources, which may help reduce the risk of immune reactions.
- Anti-CD19: The modified cells are designed to target a specific protein called CD19, which is found on certain types of immune cells.
- CAR T-cell: CAR stands for Chimeric Antigen Receptor. This is a special protein added to T-cells (a type of immune cell) that helps them recognize and attack specific targets in the body.
How KYV-101 Works
KYV-101 works by modifying a patient's own T-cells to target and eliminate cells that express CD19, a protein found on B-cells. B-cells are a type of immune cell that can sometimes malfunction and contribute to autoimmune diseases.
The process involves:
- Collecting T-cells from the patient's blood
- Modifying these T-cells in a laboratory to express the anti-CD19 CAR
- Multiplying these modified cells
- Infusing the CAR T-cells back into the patient
Once in the body, these modified T-cells can recognize and attack B-cells, potentially reducing the autoimmune response that causes disease symptoms.
Conditions Treated with KYV-101
KYV-101 is being studied for the treatment of several B cell-driven autoimmune diseases. These include:
- Idiopathic Inflammatory Myopathies (IIM): A group of conditions that cause muscle inflammation, including:
- Dermatomyositis (DM)
- Necrotizing myopathy
- Anti-HMGCoA-associated myopathy
- Polymyositis (PM)
- Diffuse Cutaneous Systemic Sclerosis (dcSSc): A condition that causes hardening and tightening of the skin and internal organs
- Systemic Lupus Erythematosus (SLE) with nephritis: An autoimmune disease that can affect various parts of the body, particularly the kidneys in this case
- ANCA-Associated Vasculitis (AAV): A group of diseases that cause inflammation of blood vessels
How KYV-101 is Administered
KYV-101 is administered as a single intravenous (IV) infusion. The dosage used in current clinical trials is 1×10^8 CAR+ T cells.
Before receiving KYV-101, patients undergo a process called lymphodepletion. This involves receiving chemotherapy drugs to reduce the number of existing immune cells in the body. The drugs used are:
- Cyclophosphamide: 300 mg/m2
- Fludarabine: 30 mg/m2
These drugs are given intravenously daily for 3 days, typically 5 to 7 days before the KYV-101 infusion.
Current Clinical Trials
There are currently two clinical trials studying KYV-101:
- CARTIMMUNE Study (NCT06152172): This trial is studying KYV-101 in patients with various autoimmune diseases, including IIM, dcSSc, SLE with nephritis, and AAV. It aims to enroll up to 24 participants who will receive a single dose of KYV-101 and be followed for 2 years.
- ANCA Vasculitis Study (NCT06590545): This is a Phase I/II trial specifically focusing on patients with ANCA-IgG-positive AAV. The study aims to assess the safety and efficacy of KYV-101 in these patients, with a follow-up time of 52 weeks.
Safety and Efficacy
The primary focus of the current clinical trials is to assess the safety and efficacy of KYV-101. Key aspects being monitored include:
- Incidence and severity of adverse events (AEs)
- Occurrence of cytokine release syndrome (CRS) or immune cell-associated neurotoxicity syndrome (ICANS)
- Clinical efficacy in treating the targeted autoimmune conditions
- ANCA seroconversion rate (for the ANCA vasculitis trial)
It's important to note that as KYV-101 is still in clinical trials, its full safety profile and efficacy are not yet established.
Potential Benefits of KYV-101
While the full benefits of KYV-101 are still being studied, researchers hope this therapy could offer several advantages for patients with autoimmune diseases:
- Potential for long-term remission or even cure of the autoimmune condition
- Possibility of reducing or eliminating the need for ongoing immunosuppressive medications
- Targeted approach that specifically addresses B-cell driven autoimmune processes
- Single infusion treatment, which could be more convenient than ongoing therapies
However, it's crucial to remember that these potential benefits are still being investigated in clinical trials, and more research is needed to confirm the long-term effects and efficacy of KYV-101.